ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint
December 20, 2019Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company (Lilly), failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure. -
Boehringer Ingelheim, Lilly Provides Update on Jardiance Study
December 18, 2019Boehringer Ingelheim and Eli Lilly and Company announced results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance® (empagliflozin) ...
Pharma Sources Insight January 2025
